

Sanjeev Kumar, Ph.D.
Senior Vice President
Biologics and Biosimilar Division, Zydus Cadila
India

Title: Developing and Launching Exemptia™ as the First Biosimilar of Adalimumab

Abstract:

Exemptia™ is the brand name for Zydus' Adalimumab which is designed to be highly biosimilar to the originator's product. A number of physicochemical and biological tests have been used to study the degree of biosimilarity. Data from selected such tests will be discussed to support this argument of high biosimilarity. Exemptia™ was the first biosimilar of Adalimumab to be launched anywhere in the world.